The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign

P. Barozzi, M. Luppi, K. Cagossi, A. Maiorana, R. Marasca, T. Artusi, S. Poggi, S. A. Pileri, G. Torelli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: In vitro studies have shown that the 30 and 69 base pair (bp) deletion variants of the latent membrane protein (LMP)-1 gene of the Epstein-Barr virus (EBV) have a higher transforming capacity than the wild- type variant. In recent years these studies have triggered an in vivo search for such potentially oncogenic variants in lymphoid tissues. Patients and methods: We used polymerase chain reaction (PCR) to investigate the prevalence of LMP-1 gene variants in EBV-positive lymph nodes from 60 HIV- negative Italian patients with benign and malignant lymphoid disorders. Results: The 30 bp variant was detected in 10 of 39 (25.6%) malignant lymphomas but also in 4 of 13 (30%) reactive lymphadenitis with follicular hyperplasia. Of note is the fact that the 69 bp variant was detected in three cases of malignant lymphoproliferation but also in two cases of localized Castleman's disease of hyalin vascular type. Conclusions: The molecular detection of the oncogenic variants of the LMP-1 gene in a lymph node biopsy as an indicator of the aggressiveness of the EBV-associated lymphoproliferative disease must be considered with caution. The relatively high frequency of the 69 bp variant in our series compared with that reported in the literature probably reflects a different incidence of LMP-1 variants in healthy populations from different geographical areas.

Original languageEnglish
Pages (from-to)467-469
Number of pages3
JournalAnnals of Oncology
Volume10
Issue number4
DOIs
Publication statusPublished - 1999

Fingerprint

Base Pairing
HIV
Membrane Proteins
Human Herpesvirus 4
Genes
Lymph Nodes
Giant Lymph Node Hyperplasia
Lymphadenitis
Hyalin
Lymphoid Tissue
Hyperplasia
Blood Vessels
Lymphoma
Biopsy
Polymerase Chain Reaction
Epstein-Barr virus EBV-associated membrane antigen
Incidence
Population

Keywords

  • Epstein-Barr virus
  • LMP-1
  • Lymphoid disorders

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. / Barozzi, P.; Luppi, M.; Cagossi, K.; Maiorana, A.; Marasca, R.; Artusi, T.; Poggi, S.; Pileri, S. A.; Torelli, G.

In: Annals of Oncology, Vol. 10, No. 4, 1999, p. 467-469.

Research output: Contribution to journalArticle

Barozzi, P. ; Luppi, M. ; Cagossi, K. ; Maiorana, A. ; Marasca, R. ; Artusi, T. ; Poggi, S. ; Pileri, S. A. ; Torelli, G. / The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. In: Annals of Oncology. 1999 ; Vol. 10, No. 4. pp. 467-469.
@article{5b77e1590ce147c9a785ba9deb984d7d,
title = "The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign",
abstract = "Background: In vitro studies have shown that the 30 and 69 base pair (bp) deletion variants of the latent membrane protein (LMP)-1 gene of the Epstein-Barr virus (EBV) have a higher transforming capacity than the wild- type variant. In recent years these studies have triggered an in vivo search for such potentially oncogenic variants in lymphoid tissues. Patients and methods: We used polymerase chain reaction (PCR) to investigate the prevalence of LMP-1 gene variants in EBV-positive lymph nodes from 60 HIV- negative Italian patients with benign and malignant lymphoid disorders. Results: The 30 bp variant was detected in 10 of 39 (25.6{\%}) malignant lymphomas but also in 4 of 13 (30{\%}) reactive lymphadenitis with follicular hyperplasia. Of note is the fact that the 69 bp variant was detected in three cases of malignant lymphoproliferation but also in two cases of localized Castleman's disease of hyalin vascular type. Conclusions: The molecular detection of the oncogenic variants of the LMP-1 gene in a lymph node biopsy as an indicator of the aggressiveness of the EBV-associated lymphoproliferative disease must be considered with caution. The relatively high frequency of the 69 bp variant in our series compared with that reported in the literature probably reflects a different incidence of LMP-1 variants in healthy populations from different geographical areas.",
keywords = "Epstein-Barr virus, LMP-1, Lymphoid disorders",
author = "P. Barozzi and M. Luppi and K. Cagossi and A. Maiorana and R. Marasca and T. Artusi and S. Poggi and Pileri, {S. A.} and G. Torelli",
year = "1999",
doi = "10.1023/A:1008381006612",
language = "English",
volume = "10",
pages = "467--469",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign

AU - Barozzi, P.

AU - Luppi, M.

AU - Cagossi, K.

AU - Maiorana, A.

AU - Marasca, R.

AU - Artusi, T.

AU - Poggi, S.

AU - Pileri, S. A.

AU - Torelli, G.

PY - 1999

Y1 - 1999

N2 - Background: In vitro studies have shown that the 30 and 69 base pair (bp) deletion variants of the latent membrane protein (LMP)-1 gene of the Epstein-Barr virus (EBV) have a higher transforming capacity than the wild- type variant. In recent years these studies have triggered an in vivo search for such potentially oncogenic variants in lymphoid tissues. Patients and methods: We used polymerase chain reaction (PCR) to investigate the prevalence of LMP-1 gene variants in EBV-positive lymph nodes from 60 HIV- negative Italian patients with benign and malignant lymphoid disorders. Results: The 30 bp variant was detected in 10 of 39 (25.6%) malignant lymphomas but also in 4 of 13 (30%) reactive lymphadenitis with follicular hyperplasia. Of note is the fact that the 69 bp variant was detected in three cases of malignant lymphoproliferation but also in two cases of localized Castleman's disease of hyalin vascular type. Conclusions: The molecular detection of the oncogenic variants of the LMP-1 gene in a lymph node biopsy as an indicator of the aggressiveness of the EBV-associated lymphoproliferative disease must be considered with caution. The relatively high frequency of the 69 bp variant in our series compared with that reported in the literature probably reflects a different incidence of LMP-1 variants in healthy populations from different geographical areas.

AB - Background: In vitro studies have shown that the 30 and 69 base pair (bp) deletion variants of the latent membrane protein (LMP)-1 gene of the Epstein-Barr virus (EBV) have a higher transforming capacity than the wild- type variant. In recent years these studies have triggered an in vivo search for such potentially oncogenic variants in lymphoid tissues. Patients and methods: We used polymerase chain reaction (PCR) to investigate the prevalence of LMP-1 gene variants in EBV-positive lymph nodes from 60 HIV- negative Italian patients with benign and malignant lymphoid disorders. Results: The 30 bp variant was detected in 10 of 39 (25.6%) malignant lymphomas but also in 4 of 13 (30%) reactive lymphadenitis with follicular hyperplasia. Of note is the fact that the 69 bp variant was detected in three cases of malignant lymphoproliferation but also in two cases of localized Castleman's disease of hyalin vascular type. Conclusions: The molecular detection of the oncogenic variants of the LMP-1 gene in a lymph node biopsy as an indicator of the aggressiveness of the EBV-associated lymphoproliferative disease must be considered with caution. The relatively high frequency of the 69 bp variant in our series compared with that reported in the literature probably reflects a different incidence of LMP-1 variants in healthy populations from different geographical areas.

KW - Epstein-Barr virus

KW - LMP-1

KW - Lymphoid disorders

UR - http://www.scopus.com/inward/record.url?scp=0032907444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032907444&partnerID=8YFLogxK

U2 - 10.1023/A:1008381006612

DO - 10.1023/A:1008381006612

M3 - Article

C2 - 10370791

AN - SCOPUS:0032907444

VL - 10

SP - 467

EP - 469

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -